

Title (en)
STIMULATION OF OSTEOGENESIS USING RANK LIGAND FUSION PROTEINS

Title (de)
STIMULATION DER OSTEOGENESE MIT RANG-LIGANDENFUSIONS-PROTEINEN

Title (fr)
STIMULATION D'OSTEOGENESE UTILISANT DES PROTEINES DE FUSION DE LIGANDS RANK

Publication
EP 1385532 A4 20041215 (EN)

Application
EP 02741650 A 20020322

Priority
• US 0209271 W 20020322
• US 27785501 P 20010322
• US 31116301 P 20010809
• US 32887601 P 20011012
• US 32923101 P 20011012
• US 32939301 P 20011015

Abstract (en)
[origin: WO02080955A1] A method of enhancing bone formation comprising administering an effective amount of 1) an oligomeric complex of one or more of RANKL, a RANKL fusion protein or an analog, derivative or mimic thereof, 2) an osteogenic compound capable of enhancing activity of one or more intracellular proteins in osteoblasts or osteoblast precursors, wherein said activity is indicative of bone formation, or 3) an osteogenic compound capable of inactivating one or more phosphatases in osteoblasts or osteoblast precursors, wherein said inactivation is indicative of bone formation. The method also may be used to treat a disease or condition manifested at least in part by the loss of bone mass by administering to a patient a pharmaceutical composition comprising an oligomeric complex or osteogenic compound disclosed herein.

IPC 1-7
A61K 38/00; **C07K 14/00**; **A61K 38/16**; **A61P 19/08**

IPC 8 full level
A61K 38/00 (2006.01); **A61K 31/197** (2006.01); **A61K 31/565** (2006.01); **A61K 31/593** (2006.01); **A61K 31/663** (2006.01); **A61K 33/06** (2006.01); **A61K 38/17** (2006.01); **A61K 38/22** (2006.01); **A61P 1/02** (2006.01); **A61P 3/14** (2006.01); **A61P 5/38** (2006.01); **A61P 7/00** (2006.01); **A61P 19/00** (2006.01); **A61P 19/02** (2006.01); **A61P 19/08** (2006.01); **A61P 19/10** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 35/04** (2006.01); **C07K 14/705** (2006.01); **C12Q 1/42** (2006.01); **C12Q 1/48** (2006.01); **G01N 33/68** (2006.01)

CPC (source: EP)
A61K 38/1709 (2013.01); **A61P 1/02** (2017.12); **A61P 3/14** (2017.12); **A61P 5/38** (2017.12); **A61P 7/00** (2017.12); **A61P 19/00** (2017.12); **A61P 19/02** (2017.12); **A61P 19/08** (2017.12); **A61P 19/10** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 35/04** (2017.12); **C07K 14/70575** (2013.01); **C12Q 1/42** (2013.01); **C12Q 1/485** (2013.01); **G01N 33/6863** (2013.01); **C07K 2319/00** (2013.01); **G01N 2500/10** (2013.01)

C-Set (source: EP)
A61K 38/1709 + **A61K 2300/00**

Citation (search report)
• [XP] WO 0142298 A1 20010614 - KORNBLUTH RICHARD S [US]
• [X] WO 0015807 A1 20000323 - M & E BIOTECH A S [DK], et al
• [X] WO 9958674 A2 19991118 - IMMUNEX CORP [US], et al
• [XP] LAM J ET AL: "RANK ligand stimulates anabolic bone formation", September 2001, JOURNAL OF BONE AND MINERAL RESEARCH, VOL. 16, NR. SUPPL. 1, PAGE(S) S150, TWENTY-THIRD ANNUAL MEETING OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH; PHOENIX, ARIZONA, USA; OCTOBER 12-16, 2001, ISSN: 0884-0431, XP009038403
• [A] LACEY D L ET AL: "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 93, no. 2, 17 April 1998 (1998-04-17), pages 165 - 176, XP002117567, ISSN: 0092-8674
• [A] KONG Y-Y ET AL: "Osteoprotegerin ligand: a regulator of immune responses and bone physiology", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 10, 1 October 2000 (2000-10-01), pages 495 - 502, XP004217459, ISSN: 0167-5699
• See references of WO 02080955A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 02080955 A1 20021017; CA 2441538 A1 20021017; EA 200301041 A1 20040826; EP 1385532 A1 20040204; EP 1385532 A4 20041215; JP 2004526748 A 20040902

DOCDB simple family (application)
US 0209271 W 20020322; CA 2441538 A 20020322; EA 200301041 A 20020322; EP 02741650 A 20020322; JP 2002578994 A 20020322